Information Provided By: 
Fly News Breaks for August 7, 2018
SAGE
Aug 7, 2018 | 08:02 EDT
Stifel transferred coverage of Sage Therapeutics to analyst Paul Matteis, who set a Buy rating and $239 price target on the shares. Matteis sees a high likelihood path for SAGE-217 to become a $3B-$5B product across an array of psychiatric indications. He also expects FDA approval of Sage's brexanolone for postpartum depression by the end of this year.
News For SAGE From the Last 2 Days
There are no results for your query SAGE
